晚期卵巢癌初次与中间型肿瘤细胞减灭术术后结局:荷兰妇科肿瘤审计登记研究
该研究基于荷兰妇科肿瘤审计(DGOA)2015—2018年数据,回顾分析1027例初次肿瘤细胞减灭术(PDS)与1355例中间型减灭术(IDS)患者。PDS组需再次干预的并发症显著高于IDS组(5.7% vs 3.6%,p=0.048),完全减灭率PDS为69.7%、IDS为62.1%(p<0.001)。
要点
- PDS组需再次干预并发症5.7%,高于IDS组3.6%(p=0.048)。
- PDS完全减灭率69.7%,IDS为62.1%(p<0.001)。
- 完全减灭且需再次干预者辅助化疗起始时间为49天。
核心结论
- PDS组完全减灭率更高提示患者选择正确,但需再次干预的并发症比例更高,导致辅助化疗起始时间延长。
- 强调需在手术积极程度与严重并发症结局之间保持平衡,并建议在全国层面讨论基准数据。
研究设计与样本
- 基于荷兰妇科肿瘤审计(DGOA)的回顾性分析。
- PDS组1027例,IDS组1355例。
- 采用R.Studio进行统计分析。
主要发现
- 需再次干预的并发症PDS组显著高于IDS组(5.7% vs 3.6%,p=0.048)。
- 完全细胞减灭率PDS组69.7%,IDS组62.1%(p<0.001)。
- 完全减灭且发生需再次干预并发症者,辅助化疗起始时间为49天。
- 严重并发症的区域差异分析显示一个区域超出置信区间。
临床怎么用
- 在选择PDS或IDS时,应权衡完全减灭率与需再次干预并发症风险。
- 对PDS后发生需再次干预并发症者,需关注辅助化疗启动延迟。
- 可参考全国基准数据讨论并优化手术积极程度与严重并发症的平衡。
局限性
- 为回顾性审计登记分析,可能存在登记数据偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The challenge when performing cytoreductive surgery (CRS) is to balance the benefits and risks. The aim of this study was to report short term postoperative morbidity and mortality in relation to surgical outcome in patients undergoing primary debulking surgery (PDS) or interval debulking (IDS) surgery in the Netherlands. METHODS: The Dutch Gynecological Oncology Audit (DGOA) was used for retrospective analysis. Patients undergoing PDS or IDS between January 1st, 2015 - December 31st, 2018 were included. Outcome was frequency of postoperative complications. Median time to adjuvant chemotherapy and severity of complications were related to outcome of CRS. Complications with Clavien-Dindo ≥3 were analyzed per region and case mix corrected. Statistical analysis was performed with R.Studio. RESULTS: 1027 patients with PDS and 1355 patients with IDS were included. Complications with re-invention were significantly higher in PDS compared to IDS (5.7% vs. 3.6%, p = 0.048). Complete cytoreduction was 69.7% in PDS and 62.1% IDS, p < 0.001. Time to adjuvant chemotherapy was 49 days in patients with complete CRS and a complication with re-intervention. Regional variation for severe complications showed one region outside confidence intervals. CONCLUSIONS: Higher complete cytoreduction rate in the PDS group indicates that the correct patients have been selected, but is associated with a higher percentage of complication with re-intervention. As result, time to start adjuvant chemotherapy is longer in this group. Maintaining a balance in aggressiveness of surgery and outcome of the surgical procedure with respect to severe complications is underlined. Bench marked data should be discussed nationally to improve this balance.
引用
- Baldewpersad Tewarie NMS, van Driel WJ, van Ham M, et al. Postoperative outcomes of primary and interval cytoreductive surgery for advanced ovarian cancer registered in the Dutch Gynecological Oncology Audit (DGOA). Gynecol Oncol. 2021. PMID: 34147284. doi:10.1016/j.ygyno.2021.05.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。